- Home
- AUST vs PULM Comparison
AUST vs PULM Comparison
Compare AUST & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- PULM
- Stock Information
- Founded
- AUST 2020
- PULM 2003
- Country
- AUST Canada
- PULM United States
- Employees
- AUST N/A
- PULM N/A
- Industry
- AUST
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- PULM Health Care
- Exchange
- AUST Nasdaq
- PULM Nasdaq
- Market Cap
- AUST 22.2M
- PULM 18.3M
- IPO Year
- AUST 2022
- PULM N/A
- Fundamental
- Price
- AUST $1.75
- PULM $4.32
- Analyst Decision
- AUST
- PULM
- Analyst Count
- AUST 0
- PULM 0
- Target Price
- AUST N/A
- PULM N/A
- AVG Volume (30 Days)
- AUST 89.9K
- PULM 5.2K
- Earning Date
- AUST 11-06-2025
- PULM 10-16-2025
- Dividend Yield
- AUST N/A
- PULM N/A
- EPS Growth
- AUST N/A
- PULM N/A
- EPS
- AUST N/A
- PULM N/A
- Revenue
- AUST N/A
- PULM $3,000.00
- Revenue This Year
- AUST N/A
- PULM N/A
- Revenue Next Year
- AUST N/A
- PULM $134.88
- P/E Ratio
- AUST N/A
- PULM N/A
- Revenue Growth
- AUST N/A
- PULM N/A
- 52 Week Low
- AUST $1.05
- PULM $4.26
- 52 Week High
- AUST $2.94
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- AUST 52.71
- PULM 47.71
- Support Level
- AUST $1.42
- PULM $4.32
- Resistance Level
- AUST $1.69
- PULM $4.85
- Average True Range (ATR)
- AUST 0.17
- PULM 0.24
- MACD
- AUST 0.02
- PULM -0.03
- Stochastic Oscillator
- AUST 88.01
- PULM 51.39
About AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).